Funding is essential to allow continuation of our research in the field of image guided surgery. Our donors and grant giving institutions underwrite the importance of our research and we are thankful for their long lasting and significant support.
The total value of funding awarded to the Image-Guided Surgery Research Group exceeds € 9 million.
|National Institute of Health (NIH)||Mediastinal lymph node identification in lung cancer using NIR fluorescent VATS||2016 - 2021||Subcontract Principal Investigator|
|NIH||ZW800-1: the first zwitterionic NIR fluorophore for cancer imaging and ureter mapping||2016 - 2018||Subcontract Principal Investigator|
|Stanford University||The aim of this project is to determine the safety and efficacy of using cetuximab-IRDy800 for intraoperative pancreatic cancer detection using multimodality molecular imaging||2016 - 2017||Subcontract Investigator|
|Dutch Cancer Society (KWF)||The overall aim of this project is to produce a novel fluorescent GMP-grade, tumor-specific EpCAM-targeted imaging agent that will aid surgical procedures, assist clinical decision making and improve treatment strategies for patients with rectal cancer UL2015-8089||2016 - 2019||Prinicpal investigator|
|Dutch Cancer Society (KWF)||Tumour-specific near-infrared fluorescence imaging in locally advanced and recurrent rectal cancer UL2018-11363||2018 - 2022||Project Leader|
|European Research Council (ERC)||The PRISAR project aims to develop hybrid fluorescence-labelled intraoperative tumor-margin specific probes in combination with optoacoustic equipment and postoperative targeted radiotherapy. H2020-MSCA-RISE-2014-644373||2015 - 2020||Project Leader|
|ERC||The ASTONISH project (PI Philips Research) will develop solutions for multiple healthcare applications using breakthrough core optical imaging technologies in the areas of NIRS, X-ray, PPG and multimodal data fusion. H2020-Astonish-6925470-2||2016 - 2019||Project Leader|
|KWF||The aim of this project is to provide surgical oncologists with a real-time fluorescence-based imaging technique to identify sentinel lymph nodes and tumors in breast and colorectal cancer patients for the complete and safe resection of targeted tissue. UL2010-4732||2011 - 2017||Principal Investigator|
|EU Horizon 2020||The ISPIC project aims to develop nanoparticle-based encapsulated libraries of different immunotherapeutic biomolecules for treatment after surgery as part of a novel cancer management strategy. H2020-MSCA-ITN-2015-675743||2016 - 2020||Project Leader|
|EU FP7||The CAReIOCA project aims at providing pathologists and/or surgeons novel non-invasive optical imaging at the cellular scale for fast cancer assessment using Full-Field Optical Coherence Tomography (FFOCT). FP7-ICT CARelOCA||2012 - 2016||Principal Investigator|
|KWF Bas Mulder award||The watch-and wait policy in rectal cancer patients: International, multicenter evaluation and improvement. The aim of this project is to improve oncological safety of watch and wait strategy by implementation of NIR fluorescence imaging in selection and follow-up of patients.||2016 - 2020||Supervisor Bas Mulder Award|
|KWF Bas Mulder award||This project aims to improve the quality of surgical selection and resection using novel intraoperative imaging techniques in patients with pancreatic cancer.||2015 - 2019||Supervisor Bas Mulder Award|
|Intuitive Surgical||The aim of this project is to determine the safety and efficacy of using cetuximab-IRDye800 for intraoperative pancreatic cancer detection using multimodality molecular imaging integrated in the DaVinci Surgical System.||2015 - 2016||Prinicpal Investigator|
|Completed Research (last 3 years)|
|Nuts Ohra||Clinical Testing of Folate-Targeting Agents A single center, phase 1 study on the feasibility to detect primary lung cancer and ovarian metastases during minimally invasive surgery using near-infrared fluorescence imaging and the tumor-targeted agent EC17. Nuts Ohra Frost Study||2013 - 2015||Principal Investigator|
|KWF||This grant was awarded to allow cGMP synthesis, toxicity studies and development of an assay for the plasma detection of cRGD-ZW800-1, a novel tumor-targeted fluorescent agent developed in collaboration with Prof. J.V. Frangioni. UL2012-5561||2012 - 2015||Principal Investigator|
|Center for Translational Molecular Medicine (CTMM)||The MUSIS project aimed to develop new technologies that enable rapid clinical implementation of intraoperative near-infrared fluorescence (NIRF) imaging of tumor tissue in surgical oncology, by developing tumor-targeted NIRF agents and sensitive intraoperative NIRF camera systems. CTMM MUSIS 03O-202||2009 - 2015||Project Leader|
|CTMM||DeCoDe aimed to develop and validate molecular medicine solutions (e.g. laboratory tests and molecular imaging applications) for pre-, primary and metastatic colorectal cancer, with an emphasis on early and accurate detection/population screening, individualized and optimized staging and therapy decision. CTMM DeCoDe 03O-101||2008 - 2013||Project Leader|
|Commercial Research Support Image-Guided Surgery Group (LUMC&CHDR)|
|On Target Laboratories, West Lafayette, United States||Clinical translation of folate-receptor targeted fluorescent tracers|
|SurgiMab, Montpellier, France||Intraoperative imaging of colorectal and pancreatic cancer using CEA-targeted fluorescent tracers|
|Delcath Systems Ltd., New York City, United States||Percutaneous liver perfusion with chemotherapy|
|Edinburgh Molecular Imaging (pending), Edinburgh, United Kingdom||Clinical translation of folate-receptor targeted fluorescent tracers|
To further develop this smart technology and to make it available for the patients as soon as possible, we greatly appreciate any form of your support. For more information on donating, click here or visit the website of the Bontius Stichting.
Support our research
Do you have questions on fluorescence-guided surgery? Do you want to learn more on results of our research? Contact Dr Vahrmeijer via firstname.lastname@example.org.